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Summary The relationship between oral contraceptives (OCs), menopausal hormone replacement therapy
(HRT) and the risk of colorectal cancer was investigated in a case-control study conducted in northern Italy
between 1985 and 1992 on 709 women with incident colorectal cancer and 992 controls admitted to hospital for
a wide spectrum of acute, non-neoplastic, non-digestive tract, non-hormone-related disorders. A reduced risk of
colorectal cancer was observed in women who had ever used OCs [multivariate odds ratio (OR)=0.58; 95%
confidence interval (CI): 0.36-0.92]. The OR was 0.52 (95% CI 0.27-1.02) for use over 2 years. For women
ever using HRT, the multivariate OR was 0.40 (95% CI 0.25-0.66). The risk was inversely related to duration
of use, with ORs of 0.46 for 2 years or less and 0.25 for more than 2 years of use. No consistent pattern of
trends was observed with time since first or last use. This study provides further evidence that OC and HRT do
not increase, and possibly decrease, the risk of colorectal cancer. These results, if confirmed, would have
important implications for the ultimate risk-benefit assessment of female hormone preparations.
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Cancer of the large bowel is the second leading site of cancer
in women (WHO, 1992) and over the last few decades its
incidence and mortality trends have been consistently more
favourable in women than in males in North America and in
most western European countries (Ries et al., 1991; La
Vecchia et al., 1992). This may be due to a healthier dietary
and lifestyle pattern in women, but also to a potential
protective effect of exposure to (exogenous) female hormones
in women. Such an effect of female sex hormones on
colorectal carcinogenesis is biologically plausible, as they
influence hepatic cholesterol metabolism and bile production
(McMichael and Potter, 1980), and steroid hormone
receptors have been found in colorectal cancers and normal
colonic mucosa (Singh et al., 1993; Hendrickse et al., 1993).
Furthermore, an inverse relationship between parity and
colorectal cancer risk (Potter and McMichael, 1983), as well
as an increased incidence of colorectal cancer in nuns
(Fraumeni et al., 1969), has been reported.
Several cohort and case-control studies have investigated
reproductive factors and colorectal cancer in women (La
Vecchia and Franceschi, 1991; Potter et al., 1993) but only few
have considered use of oral contraceptives and/or hormone
replacement therapy (Potter and McMichael, 1983; Wu et al.,
1987; Adami et al., 1989; Chute et al., 1991; Bostick et al.,
1994; Weiss et al., 1981; Rosenberg et al., 1987; Davis et al.,
1989; Furner et al., 1989; Peters et al., 1990; Kune et al., 1990;
Wu-Williams et al., 1991; Gerhardsson de Verdier and
London, 1992; Newcomb and Storer, 1995; Jacobs et al.,
1994; Risch and Howe, 1995; Calle et al., 1995; Folsom et al.,
1995). Among these, two studies have reported some
(although inconsistent) increased risk of colorectal cancer
among women who had used oral contraceptives (OCs) (Weiss
et al., 1981; Kune et al., 1990), and one showed a moderate
protection (Potter and McMichael, 1983). In six studies an
inverse relationship was observed for hormone replacement
therapy (HRT) (Chute et al., 1991; Furner et al., 1989;
Gerhardson de Verdier and London, 1992; Jacobs et al., 1994;
Newcomb and Storer, 1995; Calle et al., 1995). In summary,
most evidence suggests that OC and HRT use do not increase
the risk of colorectal cancer, and some data even indicate a
possible protective effect of HRT.
Given the widespread use of OCs and HRT in developed
countries, it is a major public health issue to further elucidate
this relationship. Thus, this investigation was aimed at
assessing the relationship between OC and HRT use and
colorectal cancer, using data from a case-control study
conducted in northern Italy.
Subjects and methods
The data were derived from a case-control study of
colorectal cancer conducted in northern Italy, based on a
network of teaching and general hospitals in the Greater
Milan area (the largest urban area in northern Italy, with
approximately 4 million inhabitants), and the province of
Pordenone, in north-east Italy. Recruitment of colorectal
cases and of the corresponding controls began in January
1985, and the present analysis is based on data collected
before June 1992.
The general design of this investigation has been described
previously (Negri et al., 1989; Franceschi et al., 1991). Briefly,
trained interviewers identified and questioned cases of
colorectal cancer and controls admitted to hospital using a
structured questionnaire, including information on socio-
demographic factors, personal characteristics and lifestyle
habits (such as smoking, alcohol, coffee and other
methylxanthine-containing beverage consumption), fre-
quency of consumption of 29 indicator foods, and a
problem-oriented medical history. For women, information
was also collected on menstrual and reproductive factors, and
on use of oral contraceptives, non-contraceptive oestrogens
for menopausal replacement therapy and female hormones
for other indications. The time of each episode of use was
noted, together with the brand name, whenever available.
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Cases
The casesincluded in the presentanalysis were 709 womenaged
less than 75 years (median age, 61 years) with histologically
confirmed incident (i.e. diagnosed within the year beforeExogenous female hormones and colorectal cancer
E Fernandez et a!
1432
interview) cancers ofthecolorectum. Theywere admitted to the
National Cancer Institute, to severaluniversity hospitals, orthe
Ospedale Maggiore of Milan, which includes the four largest
teaching and general hospitals in Milan, to the Aviano Cancer
Center and to all other general hospitals in the area of
Pordenone. All the interviews were conducted in hospital, and
restricted to identified surviving patients.
Controls
The comparison group included 992 women aged less than
75 years (median age, 58 years) admitted for a wide
spectrum of acute, non-neoplastic, non-digestive, non-
hormone-related disorders to the same network of hospitals
in which cases were recruited. Forty per cent were admitted
for traumatic conditions, 20% had non-traumatic orthopae-
dic disorders, 16% had acute surgical conditions, 13% eye
conditions and 11% had other miscellaneous diseases, such
as ear, nose and throat, skin, or dental disorders. About
80% of cases and controls resided in the same regions,
Lombardy and Friuli Venezia-Giulia, and more than 90%
came from northern Italy. As for cases, all the data were
collected by direct interview during a hospital stay. Less
than 3% of subjects approached (cases and controls) refused
to be interviewed.
Data analysis and controlfor confounding
Odds ratios (ORs), as estimators of relative risks, together
with the corresponding 95% confidence intervals (CIs), for
various measures of use of OCs and HRT were derived from
unconditional multiple logistic regression equations, fitted by
the method of maximum likelihood (Breslow and Day, 1980;
Baker and Nelder, 1978). Since separate analysis ofcolon and
rectal cancer provided similar results, only combined ORs are
shown. The variables included in the regression equations
were age (in decades, except for the first group defined by age
<40 years), area of residence, social class (based on the head
of the household's occupation), family history of colorectal
cancer, age at menarche ( 11, 12- 14, > 15 years) and parity
(0, 1, 2, 3 >4 births). Allowance for other potential
confounding variables (total energy intake; an indicator
variable of food consumption score based on a diet rich in
cereals and poor in vegetables and fruit; meat and alcohol
consumption; fat intake; body mass index; and smoking) did
not substantially modify any of the estimates. Allowance for
physical activity was not possible since the questionnaire used
did not comprise this factor.
Results
The distribution of colorectal cancer cases and controls
according to age and selected covariates is shown in Table I.
No significant difference was observed in social class and
parity, but cases more frequently reported a family history of
colorectal cancer (OR= 1.80; 95% CI: 1.17-2.77), and an
early menarche (OR for > 15 years vs 11 years=0.56; 95%
CI: 0.39-0.79).
Various measures of OC use are considered in Table II. A
total of 30 (4.2%) cases and 92 (9.3%) controls had ever used
OCs, yielding a multivariate OR of 0.58 (95% CI: 0.36-
0.92), and of0.52 (95% CI: 0.27- 1.02) for use >2 years. The
OR was 0.74 in women who had begun to use OCs 15 years
ago or less, and 0.42 for women who had begun more than
15 years ago. The OR was 0.64 for women who had stopped
OC use 10 or less years ago, and 0.48 for those who had
stopped 10 or more years ago.
HRT is considered in Table III. Twenty-three (3.2%) cases
vs 75 (7.6%) controls reported having ever used HRT,
corresponding to an OR of 0.40 (95% CI: 0.25-0.66). The
risk was inversely related to duration of use, with an OR of
0.46 (95% CI: 0.27-0.80) for 2 or less years and 0.25 (95%
CI: 0.08-0.77) for more than 2 years of use. Similarly to OC
use, no consistent pattern of trends was observed with
reference to time since first or last HRT use.
No interaction was apparent when the association between
OCs, HRT and colorectal cancer was investigated in separate
strata of age at diagnosis (<60, >60 years), menopausal
status (pre, post-menopausal) and parity (0, 1 -2, >3 births).
Table I Distribution of 709 female cases of colorectal cancer and 992 controls
according to age and selected covariates, Italy, 1985-92
Colorectal cancer
n (%)
Age (years)
<40
40-49
50-59
60-69
>70
Social class
Professional and managerial
Non-manual and manual skilled
Manual non-skilled
Farmers
Other, not classified
Family history of colorectal cancera
No
Yes
Age at menarche (years)
<1l
12-14
>15
Parity
Nulliparae
1
2
3
>4
aIn first-degree relatives.
41 (5.8)
78 (11.0)
193 (27.2)
253 (35.7)
144 (20.3)
50 (7.0)
251 (35.4)
309 (43.6)
26 (3.7)
73 (10.3)
659 (92.9)
50 (7.1)
119 (16.8)
487 (68.7)
103 (14.5)
129 (18.2)
166 (23.4)
213 (30.1)
154 (21.7)
47 (6.6)
Controls
n (%)
106 (10.7)
163 (16.4)
278 (28.0)
339 (34.2)
106 (10.7)
88 (8.9)
348 (35.1)
442 (44.6)
26 (2.6)
88 (8.8)
951 (95.9)
41 (4.1)
152 (15.3)
640 (64.5)
200 (20.2)
195 (19.6)
218 (22.0)
330 (33.3)
182 (18.3)
67 (6.8)Exogenous female hormones and colorectal cancer
E Fernandez et al
1433
Table H Relationship between various measures of oral contraceptive use and
colorectal cancer, Italy, 1985-92
Colorectal cancer Controls
n (%) n (%) OR (95% CI)a
Never used 679 (95.8) 900 (90.7) ib
Used at any time 30 (4.2) 92 (9.3) 0.58 (0.36-0.92)
Duration of usec (years)
.2 14 (2.0) 45 (4.5) 0.55 (0.29-1.05)
>2 13 (1.8) 43 (4.3) 0.52 (0.27-1.02)
x2[l]for trend 5.92 (P = 0.01)
Time since first use (years)
.15 19 (2.7) 52 (5.2) 0.74 (0.40-1.36)
>15 11 (1.6) 40 (4.0) 0.42 (0.21-0.85)
Time since last usec (years)
.10 13 (1.8) 39 (3.9) 0.64 (0.32-1.29)
>10 14 (2.0) 48 (4.8) 0.48 (0.25-0.91)
aObtained from multiple logistic regression including terms for age, area of residence,
social class, family history of colorectal cancer, age at menarche and parity. bReference
category. cThe sum does not add up to the total because ofmissing values.
Table III Relationship between various measures of oestrogen replacement therapy
use and colorectal cancer, Italy, 1985-92
Colorectal cancer Controls
n (%) n (%) OR (95% CI)a
Never used 686 (96.8) 917 (92.4) ib
Used at any time 23 (3.2) 75 (7.6) 0.40 (0.25-0.66)
Duration of usec (years)
.2 19 (2.7) 54 (5.4) 0.46 (0.27-0.80)
>2 4 (0.6) 20 (2.0) 0.25 (0.08-0.77)
X2[I] for trend 15.19 (P = 0.01)
Time since first use c (years)
.15 11 (1.6) 47 (4.7) 0.32 (0.16-0.64)
>15 12 (1.7) 27 (2.7) 0.54 (0.27-1.11)
Time since last usec (years)
< 10 9 (1.3) 22 (2.2) 0.57 (0.25- 1.28)
>10 13 (1.8) 42 (4.2) 0.39 (0.20-0.75)
aObtained from multiple logistic regression including terms for age, area of residence,
social class, family history of colorectal cancer, age at menarche and parity. bReference
category. cThe sum does not add up to the total because ofmissing values.
Discussion
This study indicates that the use of OCs and HRT does not
increase the risk of colorectal cancer. Indeed, an inverse
relationship was observed, both with OC use and with HRT.
The protection with HRT was also related to duration of use.
With reference to OCs, a similar protection has been
reported by some case-control studies (Potter and McMi-
chael, 1983; Furner et al., 1989) but not in other studies
(Weiss et al., 1981; Kune et al., 1990). Further, since no
consistent time-risk relationship is evident in this data set as
well as in previous investigations [notably in the Nurses'
Health Study cohort (Chute et al., 1991)], some caution in the
interpretation of our findings is needed.
With reference to HRT, a reduction in the risk of
colorectal cancer among users has been reported by other
cohort (Chute et al., 1991; Calle et al., 1995) and case-
control studies (Furner et al., 1989; Gerhardsson de Verdier
and London, 1992). Interestingly, three other studies found
an increased reduction in risk with more recent exposure
(Jacobs et al., 1994; Calle et al., 1995; Newcomb and
Storer, 1995). Other studies (Potter and McMichael, 1983;
Wu et al., 1987; Adami et al., 1989; Bostick et al., 1994;
Weiss et al., 1981; Davis et al., 1989; Peters et al., 1990;
Wu-Williams et al., 1991; Risch and Howe, 1995; Folsom
et al., 1995) have reported no consistent association, but
none of them has shown any significant excess in the risk
of colorectal cancer.
Although the present investigation is the largest case-
control study to date published on this issue, the number of
cases and controls exposed is limited. The low frequency of
OC and HRT use in our study population is, however, in
accordance with previous estimates from the same study base
population (La Vecchia et al., 1986; Parazzini et al., 1993)
and consistent with available drug sales data in Italy [IMS
Italia (Serra and Manna, 1992)]. Thus, this study has limited
power for detailed inspection of the influence of duration and
other time factors of OCs and HRT.
The data presented here are consistent with the
observation that female hormones are protective against
colorectal carcinogenesis, and may be related to the
hypothesis that exogenous female hormones confer a
protection against colorectal cancer as a result of changes
in bile acids and lipids (McMichael and Potter, 1980). It has
been postulated that the effect should be greater or limited to
the right side of the colon (McMichael and Potter, 1980;
Potter and McMichael, 1983; McMichael and Potter, 1985).
One limitation of the present investigation is the lack ofExogenous female homones and colorectal cancer
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information on specific subsites of origin of the neoplasm in
the colon. However. separate analysis of colon and rectal
cancer did not show appreciable differences in the risk
pattern.
Further. this is a typical case-control study and. as such.
has all the related limitations and strengths (Breslow and
Day. 1980). Among the strengths of the study. the
comparable catchment area of cases and controls (i.e.
control subjects would have been referred. if affected by
colorectal cancer. to the same hospitals where cases were
identified). together with the almost complete participation.
are reassurinn azainst selection bias. A distortion of the
observed OR towards an over-estimation of the risk cannot
be disregarded. as 4000 of controls were admitted for
traumatic conditions. and the use of HRT has been
associated with a protectiv-e effect against osteoporotic
fractures (Meyer et al.. 1993: Hutchinson et al.. 1979).
However, separate comparison of cases With each of the
major diagnostic categories of controls yielded similar results.
thus providing reassurance against potential selection bias.
Cases and controls were directly interviewed in the same
setting. thus allowing reasonably comparable information to
be obtained. This may be particularly relevant for reporting
historv of drug use. since cases and hospital controls are
similarly- sensitised towards recalling medical information
(Colombo et al.. 1977: Kelly et al.. 1990).
Information bias is unlikely to have led to a sy-stematic
underreporting of hormone use by cases. because a potential
relationship between female hormones and colorectal cancer
risk was unknown to the interviewers and probably to the
subjects interviewed. With reference to confounding. the
results were virtually unmodified after allowance for several
covariates. including body mass index, total energy intake
and other dietarv indicators. As the cases are somewhat older
than the controls. it is possible that the cases had less
opportunity to be treated with HRT. No temporal
confounding effect b- the calendar time of advent of HRT
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